Hong Qin
Corporate Officer/Principal chez Beijing Advaccine Biotechnology Co., Ltd.
Profil
Hong Qin is currently the Vice President at Beijing Advaccine Biotechnology Co., Ltd.
Prior to this, she held the position of Chief Operating Officer at Teddy Clinical Research Laboratory Shanghai Ltd.
from 2017 to 2021.
She was also the Vice President-Operations at Shanghai Ark Biopharmaceutical Co., Ltd.
from 2015 to 2017 and the Operation Director at Promega (Shanghai) Biological Products Ltd.
from 2010 to 2011.
Additionally, she worked as a Senior Manager at Shanghai Invitrogen Biotechnology Co., Ltd.
from 2011 to 2012.
Ms. Qin received her graduate degree from Texas Tech University in 1994 and another graduate degree from Nanjing Normal University in 1988.
Postes actifs de Hong Qin
| Sociétés | Poste | Début |
|---|---|---|
Beijing Advaccine Biotechnology Co., Ltd.
 Beijing Advaccine Biotechnology Co., Ltd. BiotechnologyHealth Technology Beijing Advaccine Biotechnology Co., Ltd. engages in the research and development of prophylactic and therapeutic vaccines. Its pipeline focuses on the treatment of diseases caused by SARS-CoV-2, respiratory syncytial virus, and hepatitis B virus. The company was founded by Bin Wang in April 2009 and is headquartered in Suzhou, China. | Corporate Officer/Principal | 29/03/2021 |
Anciens postes connus de Hong Qin
| Sociétés | Poste | Fin |
|---|---|---|
| Teddy Clinical Research Laboratory Shanghai Ltd. | Directeur des opérations | 01/03/2021 |
Shanghai Ark Biopharmaceutical Co., Ltd.
 Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Directeur des opérations | 01/04/2017 |
| Shanghai Invitrogen Biotechnology Co. , Ltd. | Corporate Officer/Principal | 01/04/2012 |
| Promega (Shanghai) Biological Products Ltd. | Directeur des opérations | 01/04/2011 |
Formation de Hong Qin
| Nanjing Normal University | Graduate Degree |
| Texas Tech University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
 | Health Technology |
| Entreprise privées | 4 |
|---|---|
| Teddy Clinical Research Laboratory Shanghai Ltd. | |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Health Technology |
| Promega (Shanghai) Biological Products Ltd. | |
| Shanghai Invitrogen Biotechnology Co. , Ltd. |
